Jun 11, 2020
Precigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum
Jun 04, 2020
Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders
May 06, 2020
Precigen Reports First Quarter 2020 Financial Results
Apr 29, 2020
Precigen to Announce First Quarter 2020 Financial Results on May 6th
Apr 20, 2020
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse(TM) Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Feb 24, 2020
Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd
Jan 06, 2020
Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T(TM) in Patients with Acute Myeloid Leukemia (AML)
Jan 02, 2020
Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus
Aug 05, 2019
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T(TM) in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Jun 13, 2019
Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
Feb 20, 2019
Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference
Feb 11, 2019
Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T(TM) to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients
Dec 31, 2018
Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference
Dec 21, 2018
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T(TM) Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS)
May 21, 2018
Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
Jun 29, 2017
Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen